LISATA THERAPEUTICS Business Summary

Lisata Therapeutics, Inc. (LSTA) operates as a clinical-stage pharmaceutical company primarily generating revenue through strategic R&D collaborations, upfront licensing fees, and milestone-based payments, such as its non-exclusive license agreement with Catalent and previous partnerships with Qilu Pharmaceutical. The company’s business is concentrated in a single segment: the development of its proprietary CendR Platform® technology, which utilizes the C-end rule (CendR) active transport mechanism to enhance the delivery of anti-cancer therapies into solid tumors. Its lead product candidate, certepetide (LSTA1), is currently being evaluated in multiple Phase 2 trials for indications including pancreatic ductal adenocarcinoma and glioblastoma multiforme. As of March 2026, Lisata is in the process of being acquired by Kuva Labs in an all-cash tender offer valued at approximately $5.00 per share plus contingent value rights. Within the competitive landscape, Lisata contends with small-cap biotech firms like Tonix Pharmaceuticals, Corbus Pharmaceuticals, Adagene, and Capricor Therapeutics, distinguishing itself through its unique focus on tumor-selective penetration rather than traditional cytotoxic or immunotherapy mechanisms alone. Lisata was formed through the 2022 merger of Caladrius Biosciences and Cend Therapeutics, the latter of which was founded by renowned cancer researcher Dr. Erkki Ruoslahti, whose work on the iRGD peptide forms the basis of the CendR platform. The current leadership team is headed by President and CEO David J. Mazzo, Ph.D., who brings over 35 years of pharmaceutical experience from roles at Caladrius, Regado Biosciences, and Schering-Plough. Key executives include Dr. Kristen K. Buck (EVP of R&D and Chief Medical Officer), formerly of Optum and the FDA, and James Nisco (SVP of Finance and Chief Accounting Officer). The company’s Board of Directors is chaired by Steven M. Klosk, former CEO of Cambrex Corporation, and includes industry veterans such as Cynthia L. Flowers and Dr. Mohammad Azab. Notable institutional backing has historically included specialized biotech investors, and the board’s unanimous approval of the Kuva Labs acquisition underscores a strategic pivot toward maximizing shareholder value through a definitive exit.